We are live on ! Find out more
BLFS icon

BioLife Solutions

165 hedge funds and large institutions have $690M invested in BioLife Solutions in 2022 Q4 according to their latest regulatory filings, with 15 funds opening new positions, 57 increasing their positions, 53 reducing their positions, and 23 closing their positions.

New
Increased
Maintained
Reduced
Closed

1,324% more call options, than puts

Call options by funds: $1.05M | Put options by funds: $74K

8% more repeat investments, than reductions

Existing positions increased: 57 | Existing positions reduced: 53

0.89% less ownership

Funds ownership: 90.14%89.25% (-0.89%)

5% less funds holding

Funds holding: 174165 (-9)

21% less capital invested

Capital invested by funds: $874M → $690M (-$184M)

35% less first-time investments, than exits

New positions opened: 15 | Existing positions closed: 23

75% less funds holding in top 10

Funds holding in top 10: 41 (-3)

Holders
165
Holders Change
-9
Holders Change %
-5.17%
% of All Funds
2.65%
Holding in Top 10
1
Holding in Top 10 Change
-3
Holding in Top 10 Change %
-75%
% of All Funds
0.02%
New
15
Increased
57
Reduced
53
Closed
23
Calls
$1.05M
Puts
$74K
Net Calls
+$980K
Net Calls Change
+$1.21M
Name Holding Trade Value Shares
Change
Change in
Stake
CC
1
Casdin Capital
New York
$138M
BlackRock
2
BlackRock
New York
$99.7M +$1.26M +61,011 +1%
Vanguard Group
3
Vanguard Group
Pennsylvania
$44.9M +$1.06M +51,420 +2%
FAM
4
Fred Alger Management
New York
$36M -$3.83M -185,557 -9%
GCM
5
Geneva Capital Management
Wisconsin
$27.7M -$363K -17,583 -1%
Ameriprise
6
Ameriprise
Minnesota
$20.6M +$226K +10,959 +1%
State Street
7
State Street
Massachusetts
$19.2M -$3.57M -172,919 -14%
PCM
8
Palisade Capital Management
New Jersey
$18.7M +$2.21M +107,080 +12%
Jennison Associates
9
Jennison Associates
New York
$18.1M +$8.05M +389,812 +65%
PWAM
10
Park West Asset Management
California
$17.3M +$19.6M +950,986 New
GIM
11
Granahan Investment Management
Massachusetts
$15.4M +$2.19M +105,908 +14%
Invesco
12
Invesco
Georgia
$14.5M +$548K +26,548 +3%
Millennium Management
13
Millennium Management
New York
$12.2M -$2.03M -98,110 -13%
Geode Capital Management
14
Geode Capital Management
Massachusetts
$11.8M +$564K +27,296 +4%
GS
15
Gagnon Securities
New York
$10.2M -$68.2K -3,301 -0.6%
JP Morgan Chase
16
JP Morgan Chase
New York
$7.35M -$34.1K -1,652 -0.4%
SIMG
17
Stephens Investment Management Group
Texas
$7.1M -$14.7K -712 -0.2%
ZDA
18
Zweig-DiMenna Associates
New York
$7.01M +$330K +16,000 +4%
Northern Trust
19
Northern Trust
Illinois
$6.98M +$179K +8,657 +2%
New York State Common Retirement Fund
20
New York State Common Retirement Fund
New York
$6.43M +$839K +40,635 +13%
Thrivent Financial for Lutherans
21
Thrivent Financial for Lutherans
Minnesota
$6.24M +$88.2K +4,273 +1%
Morgan Stanley
22
Morgan Stanley
New York
$6.12M -$3.23M -156,504 -32%
CRC
23
Curi RMB Capital
Illinois
$6.02M -$268K -12,966 -4%
RIM
24
Ranger Investment Management
Texas
$5.9M +$146K +7,087 +2%
Bank of New York Mellon
25
Bank of New York Mellon
New York
$5.77M -$690K -33,425 -10%

BLFS Hedge Fund Activity: Q4 2022 in Review

165 of the 6,221 institutional investors tracked by Wall St. Rank reported a position in BioLife Solutions (BLFS) for Q4 2022, worth a combined $690M — down 21% from $874M a quarter earlier.

Sellers outnumbered buyers: 23 funds closed out of BLFS and 15 opened new positions — a net loss of 8 holders — while 53 trimmed existing stakes and 57 added.

The largest buyer was Park West Asset Management, opening a new position worth an estimated $19.6M. The largest seller was TimesSquare Capital Management, exiting entirely with an estimated $12.5M sold.

  • 165 institutional investors held BioLife Solutions (BLFS) as of Q4 2022, down from 174 in Q3 2022.
  • Funds reported $690M of BioLife Solutions stock for Q4 2022, down 21% quarter-over-quarter.
  • 15 funds opened new BioLife Solutions positions in Q4 2022 and 23 closed out, a net change of -8 holders.
  • The largest BioLife Solutions buyer in Q4 2022 was Park West Asset Management, an estimated $19.6M added.
  • The largest BioLife Solutions seller in Q4 2022 was TimesSquare Capital Management, an estimated $12.5M sold.

Based on aggregated 13F filings for Q4 2022.